195 related articles for article (PubMed ID: 36460677)
1. Immunosuppressive biomaterial-based therapeutic vaccine to treat multiple sclerosis via re-establishing immune tolerance.
Nguyen TL; Choi Y; Im J; Shin H; Phan NM; Kim MK; Choi SW; Kim J
Nat Commun; 2022 Dec; 13(1):7449. PubMed ID: 36460677
[TBL] [Abstract][Full Text] [Related]
2. ROS-Scavenging Lignin-Based Tolerogenic Nanoparticle Vaccine for Treatment of Multiple Sclerosis.
Phan NM; Nguyen TL; Shin H; Trinh TA; Kim J
ACS Nano; 2023 Dec; 17(24):24696-24709. PubMed ID: 38051295
[TBL] [Abstract][Full Text] [Related]
3. Administration of ROS-Scavenging Cerium Oxide Nanoparticles Simply Mixed with Autoantigenic Peptides Induce Antigen-Specific Immune Tolerance against Autoimmune Encephalomyelitis.
Nguyen TL; Phan NM; Kim J
ACS Appl Mater Interfaces; 2024 Jun; ():. PubMed ID: 38906850
[TBL] [Abstract][Full Text] [Related]
4. A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4
Moorman CD; Curtis AD; Bastian AG; Elliott SE; Mannie MD
Front Immunol; 2018; 9():3119. PubMed ID: 30687323
[TBL] [Abstract][Full Text] [Related]
5. Treatment of autoimmune disease by oral tolerance to autoantigens.
Whitacre CC; Gienapp IE; Meyer A; Cox KL; Javed N
Clin Immunol Immunopathol; 1996 Sep; 80(3 Pt 2):S31-9. PubMed ID: 8811061
[TBL] [Abstract][Full Text] [Related]
6. Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.
Kleist C; Mohr E; Gaikwad S; Dittmar L; Kuerten S; Platten M; Mier W; Schmitt M; Opelz G; Terness P
J Transl Med; 2016 May; 14(1):99. PubMed ID: 27131971
[TBL] [Abstract][Full Text] [Related]
7. Direct modulation of myelin-autoreactive CD4
Pei W; Wan X; Shahzad KA; Zhang L; Song S; Jin X; Wang L; Zhao C; Shen C
Int J Nanomedicine; 2018; 13():3731-3750. PubMed ID: 29983566
[TBL] [Abstract][Full Text] [Related]
8. Tolerogenic vaccines for Multiple sclerosis.
Mannie MD; Curtis AD
Hum Vaccin Immunother; 2013 May; 9(5):1032-8. PubMed ID: 23357858
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis.
Cappellano G; Woldetsadik AD; Orilieri E; Shivakumar Y; Rizzi M; Carniato F; Gigliotti CL; Boggio E; Clemente N; Comi C; Dianzani C; Boldorini R; Chiocchetti A; Renò F; Dianzani U
Vaccine; 2014 Sep; 32(43):5681-9. PubMed ID: 25149432
[TBL] [Abstract][Full Text] [Related]
10. Development of PLGA Nanoparticles with a Glycosylated Myelin Oligodendrocyte Glycoprotein Epitope (MOG
Triantafyllakou I; Clemente N; Khetavat RK; Dianzani U; Tselios T
Mol Pharm; 2022 Nov; 19(11):3795-3805. PubMed ID: 36098508
[TBL] [Abstract][Full Text] [Related]
11. Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis.
LaMothe RA; Kolte PN; Vo T; Ferrari JD; Gelsinger TC; Wong J; Chan VT; Ahmed S; Srinivasan A; Deitemeyer P; Maldonado RA; Kishimoto TK
Front Immunol; 2018; 9():281. PubMed ID: 29552007
[TBL] [Abstract][Full Text] [Related]
12. Antigen-oriented T cell migration contributes to myelin peptide induced-EAE and immune tolerance.
Zheng P; Fu H; Wei G; Wei Z; Zhang J; Ma X; Rui D; Meng X; Ming L
Clin Immunol; 2016 Aug; 169():36-46. PubMed ID: 27327113
[TBL] [Abstract][Full Text] [Related]
13. Dual peptide nanoparticle platform for enhanced antigen-specific immune tolerance for the treatment of experimental autoimmune encephalomyelitis.
Wang H; Shang J; He Z; Zheng M; Jia H; Zhang Y; Yang W; Gao X; Gao F
Biomater Sci; 2022 Jul; 10(14):3878-3891. PubMed ID: 35686489
[TBL] [Abstract][Full Text] [Related]
14. The role of costimulation in autoimmune demyelination.
Racke MK; Ratts RB; Arredondo L; Perrin PJ; Lovett-Racke A
J Neuroimmunol; 2000 Jul; 107(2):205-15. PubMed ID: 10854658
[TBL] [Abstract][Full Text] [Related]
15. DNA-based vaccines for multiple sclerosis: current status and future directions.
Fissolo N; Montalban X; Comabella M
Clin Immunol; 2012 Jan; 142(1):76-83. PubMed ID: 21163708
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis.
Casacuberta-Serra S; Costa C; Eixarch H; Mansilla MJ; López-Estévez S; Martorell L; Parés M; Montalban X; Espejo C; Barquinero J
Exp Neurol; 2016 Dec; 286():50-60. PubMed ID: 27693617
[TBL] [Abstract][Full Text] [Related]
17. Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA.
Derdelinckx J; Mansilla MJ; De Laere M; Lee WP; Navarro-Barriuso J; Wens I; Nkansah I; Daans J; De Reu H; Jolanta Keliris A; Van Audekerke J; Vanreusel V; Pieters Z; Van der Linden A; Verhoye M; Molenberghs G; Hens N; Goossens H; Willekens B; Cras P; Ponsaerts P; Berneman ZN; Martínez-Cáceres EM; Cools N
J Neuroinflammation; 2019 Aug; 16(1):167. PubMed ID: 31416452
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Ligand Bioengineered Schwann Cells as Antigen-Specific Therapy for Experimental Autoimmune Encephalomyelitis.
Au KM; Tisch R; Wang AZ
Adv Mater; 2022 Feb; 34(5):e2107392. PubMed ID: 34775659
[TBL] [Abstract][Full Text] [Related]
19. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
20. Modulation of MS-like disease by a multi epitope protein is mediated by induction of CD11c
Kaushansky N; Kaminitz A; Allouche-Arnon H; Ben-Nun A
J Neuroimmunol; 2019 Aug; 333():476953. PubMed ID: 31108399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
